26 March 2019 in Ear, Nose & Throat Journal
To investigate the application of inner ear 3-dimensional fluid-attenuated inversion recovery (3D-FLAIR) magnetic resonance imaging (MRI) in patients with sudden sensorineural hearing loss (SSNHL) accompanied by inner ear hemorrhage. A total of 1252 SSNHL patients who were admitted from January 2010 to April 2018 were included in the study. The patients’ clinical features, complete blood counts, coagulation profiles, audiometry data, and MRI scans were retrospectively reviewed. Twenty-four patients had high labyrinth signals on inner ear 3D-FLAIR MRI (24/1252, 1.9%) that were diagnosed as inner ear hemorrhage. One patient had endolymphatic hydrops on the contralesional side. In the 24 patients, pure tone audiometry curves revealed profound deafness (19/24) and flat moderate hearing loss (5/24); most patients had associated vertigo (23/24) and tinnitus (19/24). Patients with SSNHL (N = 24) were treated. Sixteen patients had invalid improvement, 3 patients were markedly improved, 4 patients had effective treatment, and only 1 patient was cured, for a therapeutic efficacy of 33.3% (8/24). Follow-up 3D-FLAIR MRI in patients showed absorbance of labyrinthine hemorrhage and disappearance of the high signal intensity in the inner ear within 2 weeks to 4 months. Inner ear 3D-FLAIR MRI indicate that most cases of inner ear hemorrhage are spontaneous and that high labyrinth signals are absorbed within 4 months. The site of labyrinth hemorrhage is irregular and independent of hearing loss. Conventional treatment is not very effective, and an appropriate therapy for SSNHL requires further investigation.
3 May 2025 in Acta Oto-Laryngologica
Recent clinical trials employing AAV (adeno-associated virus)-mediated gene therapy for hereditary deafness have demonstrated significant therapeutic potential. However, immune responses triggered by AAV delivery in the inner ear remain poorly characterized, despite their critical implications for treatment safety and efficacy. This study systematically evaluates serotype-specific (AAV1 vs. AAV9) and promoter-dependent (CMV vs CBA) immune responses in murine cochleae following local AAV delivery. Recombinant AAV1/AAV9 vectors expressing tdTomato under CMV or CBA promoters were injected via the posterior semicircular canal. Macrophage infiltration (F4/80+/CD68+ cells) was tracked for five weeks via immunohistochemistry. Temporal analysis revealed inflammation onset at one week, peaking at two weeks, and resolving to baseline by five weeks. CMV-driven vectors provoked significantly stronger immune activation than CBA. Serotype comparisons showed AAV9 induced greater immunogenicity, with elevated F4/80+ cells at two weeks (p < .001) and prolonged CD68+ cell elevation through four weeks (p < .001) versus AAV1. AAV9 triggered diffuse inflammation, while AAV1 responses were modiolus-restricted. These findings highlight serotype- and promoter-dependent immunogenicity as key determinants of cochlear inflammation. Strategic selection of AAV components is essential to balance transduction efficiency and immune tolerance in inner ear gene therapy.